NEW YORK (GenomeWeb News) – The Van Andel Institute plans to become a hub of epigenetics research by developing a consortium of four US academic institutions and one from abroad that will collaborate to develop new personalized epigenetic treatments.

The initiative will be led by Peter Jones, director of research and chief scientific officer at the Van Andel Research Institute, which is based at VAI's headquarters in Grand Rapids, Mich. He already is working with international research partners on epigenetic therapies to treat cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.